Coherus Oncology, Inc. Overview
Pro stress-test →Coherus Oncology is a commercial-stage biopharmaceutical company that focuses on research, development, and commercialization of innovative immunotherapies to treat cancer. The company has an approved next-generation PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers.
Strategic Profile
Pro stress-test →The company's strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations. By 2026 the company believes its commercial product portfolio will generate more than $1.2 billion in annual net sales and position Coherus as a new leader in immuno-oncology.
Competitive Landscape
Pro stress-test →Coherus competes in the immuno-oncology space against larger established players including major pharmaceutical companies with PD-1 programs. The company competes against larger firms in the oncology market, posing threats of pricing erosion that may adversely affect its profitability. The biosimilar portfolio (UDENYCA, YUSIMRY, CIMERLI) competes in mature markets with multiple generic competitors.
Industry Context
Coherus Oncology, Inc. operates in Biopharmaceutical - Immuno-Oncology & Biosimilars.
Key facts
Founded: 2010 · Headquarters: Redwood City, California, US · Revenue: $14.1M (Q4 2025 estimate) · Market cap: $249.61M